Dr. Daniel Farray-berges, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1330 E 6th St, Suite 204
Weslaco, TX 78596
Who else practices at this address →
Hidalgo County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 317
Licensed in Texas since 2005, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license M0718 (first issued 2005; active) -
Medical Oncology Physician
TX license M0718 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Doctors Hosptal at Renaissance Edinburg, TX
- Rio Grande Regional Hospital McAllen, TX
- Knapp Medical Center Weslaco, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 317
- Services billed
- 88,735
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 10,440 | 14 |
| Injection, pembrolizumab, 1 mg | 10,200 | 15 |
| Injection, fosaprepitant, 1 mg | 6,900 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,332 | 33 |
| Insertion of needle into vein for collection of blood sample | 1,015 | 248 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 971 | 245 |
| Blood test, comprehensive group of blood chemicals | 622 | 203 |
| Injection, palonosetron hcl, 25 mcg | 550 | 23 |
| Injection, granisetron hydrochloride, 100 mcg | 460 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 430 | 123 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Weslaco, TX | 275 |
| Gabapentin Other prescribers in Weslaco, TX | 119 |
| Prednisone Other prescribers in Weslaco, TX | 82 |
| Dexamethasone Other prescribers in Weslaco, TX | 78 |
| Revlimid (lenalidomide) | 77 |
| Ondansetron Hcl Other prescribers in Weslaco, TX | 75 |
| Levothyroxine Sodium Other prescribers in Weslaco, TX | 74 |
| Olanzapine Other prescribers in Weslaco, TX | 67 |
| Exemestane | 64 |
| Letrozole Other prescribers in Weslaco, TX | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 23 payments worth $810 in total to this clinician.
| Pfizer Inc. | $189 |
|---|---|
| Boston Scientific Corporation | $138 |
| Janssen Biotech, Inc. | $79.96 |
| AstraZeneca Pharmaceuticals LP | $68.49 |
| Novartis Pharmaceuticals Corporation | $68.15 |
| GlaxoSmithKline, LLC. | $67.99 |
| Genentech USA, Inc. | $44.09 |
| Celgene Corporation | $32.03 |
| Food and Beverage | $741 |
|---|---|
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 14, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $140,560 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.